Fresenius Medical Care AG (FMS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Quarterly

0 2B 4B 6B Q3 '09: 2.9B Q3 '10: 3.1B Q2 '15: 4.2B Q3 '15: 4.2B Q1 '16: 4.2B Q2 '16: 4.4B Q3 '16: 4.6B Q3 '09 Q3 '10 Q2 '15 Q3 '15 Q1 '16 Q2 '16 Q3 '16

Gross Profit Quarterly

0 600M 1.2B 1.8B Q1 '12: 1.1B Q2 '12: 1.1B Q3 '12: 1.1B Q4 '12: 1.3B Q1 '13: 1.1B Q2 '13: 1.2B Q3 '13: 1.2B Q4 '13: 1.3B Q1 '14: 1.1B Q2 '14: 1.2B Q3 '14: 1.3B Q4 '14: 1.4B Q1 '15: 1.2B Q2 '15: 1.3B Q3 '15: 1.4B Q4 '15: 1.5B Q1 '16: 1.3B Q2 '16: 1.4B Q3 '16: 1.5B Q4 '16: 1.6B Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Operating Income Quarterly

0 300M 600M 900M Q1 '12: 503M Q2 '12: 588.8M Q3 '12: 567.6M Q4 '12: 559.1M Q1 '13: 493.3M Q2 '13: 544.2M Q3 '13: 557.3M Q4 '13: 661.4M Q1 '14: 444.9M Q2 '14: 556.3M Q3 '14: 589.9M Q4 '14: 663.4M Q1 '15: 504.4M Q2 '15: 547M Q3 '15: 613.5M Q4 '15: 661.8M Q1 '16: 540.3M Q2 '16: 641.1M Q3 '16: 669.9M Q4 '16: 786.2M Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Net Income Quarterly

0 150M 300M 450M Q1 '12: 370.5M Q2 '12: 289.3M Q3 '12: 269.9M Q4 '12: 257.1M Q1 '13: 225.5M Q2 '13: 262.5M Q3 '13: 273M Q4 '13: 348.9M Q1 '14: 205.5M Q2 '14: 233.6M Q3 '14: 270.8M Q4 '14: 335.3M Q1 '15: 209.5M Q2 '15: 240.8M Q3 '15: 262.3M Q4 '15: 316.8M Q1 '16: 228M Q2 '16: 293.9M Q3 '16: 333.2M Q4 '16: 388.1M Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Cost of Revenue Quarterly

0 1.5B 3B 4.5B Q1 '12: 2.2B Q2 '12: 2.3B Q3 '12: 2.3B Q4 '12: 2.4B Q1 '13: 2.4B Q2 '13: 2.5B Q3 '13: 2.5B Q4 '13: 2.6B Q1 '14: 2.5B Q2 '14: 2.6B Q3 '14: 2.8B Q4 '14: 2.9B Q1 '15: 2.8B Q2 '15: 2.9B Q3 '15: 2.8B Q4 '15: 2.9B Q1 '16: 2.9B Q2 '16: 3B Q3 '16: 3.1B Q4 '16: 3.1B Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Operating Cash Flow Quarterly

0 300M 600M 900M Q1 '12: 481.2M Q2 '12: 450.8M Q3 '12: 535.4M Q4 '12: 571.7M Q1 '13: 315.4M Q2 '13: 525.1M Q3 '13: 605.5M Q4 '13: 588.8M Q1 '14: 112.3M Q2 '14: 449.3M Q3 '14: 712.2M Q4 '14: 587.6M Q1 '15: 832.5M Q2 '15: 0 Q3 '15: 579.3M Q4 '15: 548.3M Q1 '16: 179.8M Q2 '16: 677.6M Q3 '16: 438.9M Q4 '16: 843.6M Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Free Cash Flow Quarterly

-1.1B -700M -350M 0 350M 700M 1.1B Q1 '12: 356.8M Q2 '12: 297.8M Q3 '12: 362.9M Q4 '12: 346.3M Q1 '13: 168.1M Q2 '13: 338.8M Q3 '13: 426.6M Q4 '13: 353.3M Q1 '14: -87.3M Q2 '14: 229.7M Q3 '14: -353.4M Q4 '14: -990.4M Q1 '15: 414.7M Q2 '15: -835.5M Q3 '15: 349.7M Q4 '15: 242.7M Q1 '16: -70.4M Q2 '16: -78.6M Q3 '16: 197.3M Q4 '16: 561.2M Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16 Q4 '16

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '19: 303.5M Q3 '19: 301.4M Q1 '20: 297.8M Q2 '20: 292.7M Q3 '20: 292.8M Q1 '21: 292.9M Q2 '21: 292.9M Q3 '21: 293M Q1 '22: 293M Q2 '22: 293.1M Q3 '22: 293.4M Q1 '23: 293.4M Q2 '23: 293.4M Q3 '23: 293.4M Q1 '24: 293.4M Q2 '24: 293.4M Q3 '24: 293.4M Q1 '25: 293.4M Q2 '25: 293.4M Q3 '25: 292.1M Q3 '19 Q3 '20 Q3 '21 Q3 '22 Q3 '23 Q3 '24 Q3 '25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 1.50 3.00 4.50 Q2 '11: 3.30 Q3 '11: 3.40 Q4 '11: 3.52 Q1 '12: 4.00 Q2 '12: 4.08 Q3 '12: 4.04 Q4 '12: 3.87 Q1 '13: 3.40 Q2 '13: 3.32 Q3 '13: 3.35 Q4 '13: 3.66 Q1 '14: 3.60 Q2 '14: 3.51 Q3 '14: 3.49 Q4 '14: 3.44 Q1 '15: 3.45 Q2 '15: 3.47 Q3 '15: 3.44 Q4 '15: 3.38 Q1 '16: 3.44 Q3 '11 Q2 '12 Q1 '13 Q4 '13 Q3 '14 Q2 '15 Q1 '16

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.